Movement Alert｜Amgen Rises 3.64% in Regular Trading, Multiple Brokerages Raise Target Prices Ahead of Earnings

Market Focus

Jul 28

On July 28, Amgen rose 3.64% in regular trading, trading at $396.1/share, with turnover of $317 million.

On the news front, Barclays raised its target price on Amgen from $350 to $360, maintaining an Equal Weight rating. This follows a series of recent upgrades including Goldman Sachs ($427, Buy), UBS ($420, Buy), and Truist Securities ($340). The FactSet consensus average target stands at approximately $357.48 with an overall Overweight rating.

Additionally, a pre-earnings preview showed market consensus expects Q2 revenue of approximately $9.425 billion, up 5.44% year-over-year, with adjusted EPS of $5.62, up 6.20% year-over-year. Amgen is scheduled to report results on August 4 after market close.

The broader biotechnology sector also showed notable strength, with Incyte up 4.64%, Alnylam Pharmaceuticals up 4.09%, AbbVie up 3.66%, Gilead Sciences up 3.33%, and Vertex Pharmaceuticals up 2.11%, reflecting a clear sector-wide uplift.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1179583577"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179583577\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179583577?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179583577","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Amgen Rises 3.64% in Regular Trading, Multiple Brokerages Raise Target Prices Ahead of Earnings","media":"Market Focus","content":"<p><p>On July 28, Amgen rose 3.64% in regular trading, trading at $396.1/share, with turnover of $317 million.</p><p>On the news front, Barclays raised its target price on Amgen from $350 to $360, maintaining an Equal Weight rating. This follows a series of recent upgrades including Goldman Sachs ($427, Buy), UBS ($420, Buy), and Truist Securities ($340). The FactSet consensus average target stands at approximately $357.48 with an overall Overweight rating.</p><p>Additionally, a pre-earnings preview showed market consensus expects Q2 revenue of approximately $9.425 billion, up 5.44% year-over-year, with adjusted EPS of $5.62, up 6.20% year-over-year. Amgen is scheduled to report results on August 4 after market close.</p><p>The broader biotechnology sector also showed notable strength, with Incyte up 4.64%, Alnylam Pharmaceuticals up 4.09%, AbbVie up 3.66%, Gilead Sciences up 3.33%, and Vertex Pharmaceuticals up 2.11%, reflecting a clear sector-wide uplift.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Amgen Rises 3.64% in Regular Trading, Multiple Brokerages Raise Target Prices Ahead of Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Amgen Rises 3.64% in Regular Trading, Multiple Brokerages Raise Target Prices Ahead of Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-28 22:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 28, Amgen rose 3.64% in regular trading, trading at $396.1/share, with turnover of $317 million.</p><p>On the news front, Barclays raised its target price on Amgen from $350 to $360, maintaining an Equal Weight rating. This follows a series of recent upgrades including Goldman Sachs ($427, Buy), UBS ($420, Buy), and Truist Securities ($340). The FactSet consensus average target stands at approximately $357.48 with an overall Overweight rating.</p><p>Additionally, a pre-earnings preview showed market consensus expects Q2 revenue of approximately $9.425 billion, up 5.44% year-over-year, with adjusted EPS of $5.62, up 6.20% year-over-year. Amgen is scheduled to report results on August 4 after market close.</p><p>The broader biotechnology sector also showed notable strength, with Incyte up 4.64%, Alnylam Pharmaceuticals up 4.09%, AbbVie up 3.66%, Gilead Sciences up 3.33%, and Vertex Pharmaceuticals up 2.11%, reflecting a clear sector-wide uplift.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMGN","symbol_name":"安进","start_time":0,"source_url":"","article_id":"1179583577","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179583577","pubTimestamp":1785248210,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 28, Amgen rose 3.64% in regular trading, trading at $396.1/share, with turnover of $317 million.On the news front, Barclays raised its target price on Amgen from $350 to $360, maintaining an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMGN":"安进"},"translate_title":"走势警报|安进常规交易上涨3.64%，多家券商在财报公布前上调目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1},"content_text":"On July 28, Amgen rose 3.64% in regular trading, trading at $396.1/share, with turnover of $317 million.On the news front, Barclays raised its target price on Amgen from $350 to $360, maintaining an Equal Weight rating. This follows a series of recent upgrades including Goldman Sachs ($427, Buy), UBS ($420, Buy), and Truist Securities ($340). The FactSet consensus average target stands at approximately $357.48 with an overall Overweight rating.Additionally, a pre-earnings preview showed market consensus expects Q2 revenue of approximately $9.425 billion, up 5.44% year-over-year, with adjusted EPS of $5.62, up 6.20% year-over-year. Amgen is scheduled to report results on August 4 after market close.The broader biotechnology sector also showed notable strength, with Incyte up 4.64%, Alnylam Pharmaceuticals up 4.09%, AbbVie up 3.66%, Gilead Sciences up 3.33%, and Vertex Pharmaceuticals up 2.11%, reflecting a clear sector-wide uplift.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}